GSK starts final-stage tests on severe asthma drug
LONDON (Reuters) - GlaxoSmithKline has started final-stage testing of an experimental drug for treating severe asthma, Britain's biggest drugmaker said on Monday.
The move to progress the injectable antibody treatment mepolizumab into Phase III trials had been expected after an earlier study showed it nearly halved the number of attacks suffered by patients.
Severe refractory asthma only affects around 4 percent of patients with the disease, so the drug may not become a major seller for GSK but could consolidate the group's strong grip on the market for lung drugs.
(Reporting by Ben Hirschler)
- Former WWE champ nabs suspected burglar in Arizona
- Thousands take to N.Y. streets to protest Israeli offensive in Gaza
- First Ebola victim in Sierra Leone capital on the run
- U.S. fighter jets escort Canadian plane home over passenger threat
- Apple iPhones allow extraction of deep personal data, researcher finds
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video